You may have to log into the site to read these. It is free to log into the site. Hi-lites of the study are:
(Explanation for DAPT: The DAPT Study is an independent, large-scale study in size and scope intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication to reduce the risk of blood clots)
(Explanation for PCI: Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty or simply angioplasty, is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease.)
"In a real-world patient population undergoing PCI, less than half of patients with a CHADS2 score ≥2 received oral anticoagulation with warfarin at hospital discharge. Despite this, rates of 5-year stroke were similar among those who did vs. did not receive oral anticoagulation."
"There is insufficient evidence surrounding the use of oral anticoagulants and dual antiplatelet therapy in atrial fibrillation among patients undergoing PCI, according to the researchers."
"The cumulative 5-year stroke rate was 13.8% among patients receiving oral anticoagulants and 11.8% among those not receiving the therapy, which the researchers noted was not significantly different (P=.49)."
"The investigators conducted a 4-month landmark analysis in the oral anticoagulation group. The stroke rate among 286 patients receiving DAPT in this analysis was 15.1% compared with 6.7% among 173 patients not receiving DAPT (P=.052). Major bleeding rates in this analysis were 14.7% for the DAPT group and 8.7% for the non-DAPT group (P=.10)."
"[Oral anticoagulation] was underused and its intensity was mostly suboptimal in ‘real world’ AF patients undergoing PCI, which led to inadequate stroke prevention,” the researchers concluded. “Long-term DAPT in patients receiving [oral anticoagulation] did not reduce stroke incidence.”